Stocksigma LogoStocksigma Logo

Anlon Healthcare Q2 FY27 Investor Presentation Highlights Strong Growth

Anlon Healthcare reported consolidated Q2 FY27 revenue of ₹10,561.0 Lacs, up 102.3% YoY and 20.6% QoQ, with EBITDA rising 84.1% YoY to ₹2,524.1 Lacs (23.9%

Anlon Healthcare Q2 FY27 Investor Presentation Highlights Strong Growth

Anlon Healthcare Ltd · Investor Presentation · 31 Oct 2026, 1:07 am

Anlon Healthcare Q2 FY27 Investor Presentation Highlights Strong Growth Anlon Healthcare reported consolidated Q2 FY27 revenue of ₹10,561.0 Lacs, up 102.3% YoY and 20.6% QoQ, with EBITDA rising 84.1% YoY to ₹2,524.1 Lacs (23.9% margin) and PAT surging 84.4% YoY to ₹1,717.8 Lacs (16.3% margin). H1 FY27 revenue reached ₹19,317.2 Lacs (+125.9% YoY) with PAT at ₹2,545.9 Lacs (+97.9% YoY). Growth is driven by core NSAID APIs, CDMO expansions (3 molecules), and recent acquisitions (Apiqo, Bizotic, Anlon Medicos), supported by ~1,200 MTPA upcoming capacity commissioning in Q1 FY28.

Original exchange filing (PDF)

More announcements from Anlon Healthcare Ltd

All Anlon Healthcare Ltd announcements